Accolade, Inc. (NASDAQ:ACCD) Given Average Recommendation of “Hold” by Analysts

Accolade, Inc. (NASDAQ:ACCD) has been assigned a consensus recommendation of “Hold” from the thirteen brokerages that are covering the company, MarketBeat reports. Eleven analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $7.55.

Several equities analysts have recently weighed in on ACCD shares. Morgan Stanley reduced their price target on Accolade from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. William Blair lowered Accolade from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 8th. Raymond James reissued a “market perform” rating on shares of Accolade in a report on Thursday, January 9th. Stifel Nicolaus reaffirmed a “hold” rating and set a $7.03 price objective (down previously from $8.00) on shares of Accolade in a research note on Thursday, January 9th. Finally, Barclays lowered their target price on shares of Accolade from $5.50 to $5.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 9th.

Insider Transactions at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $48,085.20. Following the completion of the sale, the chief executive officer now owns 814,316 shares in the company, valued at $2,931,537.60. The trade was a 1.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 41,962 shares of company stock valued at $152,424. Insiders own 8.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Mission Creek Capital Partners Inc. bought a new stake in shares of Accolade in the 3rd quarter worth approximately $38,000. Pallas Capital Advisors LLC bought a new stake in Accolade in the fourth quarter worth $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Accolade during the third quarter valued at about $46,000. Wolverine Trading LLC bought a new position in shares of Accolade during the third quarter valued at about $51,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Accolade by 1,144.1% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock worth $81,000 after buying an additional 19,232 shares during the period. 84.99% of the stock is currently owned by institutional investors.

Accolade Price Performance

NASDAQ ACCD opened at $6.84 on Wednesday. The company has a market cap of $550.87 million, a PE ratio of -6.64 and a beta of 2.08. The company has a quick ratio of 2.72, a current ratio of 2.72 and a debt-to-equity ratio of 0.49. The firm’s 50-day simple moving average is $3.88 and its two-hundred day simple moving average is $3.83. Accolade has a 52 week low of $3.08 and a 52 week high of $13.93.

Accolade (NASDAQ:ACCD) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. Research analysts predict that Accolade will post -0.92 earnings per share for the current year.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.